Recent Publications
Gallagher PE, Maglic D, Krishnan B, Castellino SM, Tallant EA.
Angiotensin-(1-7) inhibits the growth of human pediatric rhabdomyosarcoma in a mouse xenograft model [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando (FL). Philadelphia (PA): AACR.
2011;
():Abstr 5349.
Carver KA, Smith TL, Gallagher PE, Tallant EA.
Angiotensin-(1-7) attenuates angiotensin II-induced fibrosis through a reduction in connective tissue growth factor [abstract]. Hypertension.
2011;
58(5):e178.
Tallant EA, Carver KA, Gallagher PE.
Angiotensin-(1-7) reduces cardiac hypertrophy and fibrosis in mRen2.Lewis congenic rats [abstract]. Hypertension.
2011;
58(5):e110.
Tallant EA, Holmes CH, Gallagher PE.
Inhibition of cancer cell growth by muscadine grape seed and grape skin extracts [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, Florida. Philadelphia (PA): AACR.
2011;
():Abstr 4220.
Nautiyal M, Tallant EA, Chappell MC, Diz DI.
Mitogen-activated protein kinase phosphatase-1 (MKP-1) is low in dorsal medulla of hypertensive (mRen2)27 transgenic rats [abstract]. FASEB J.
2010;
24(1 Meeting Abstracts):955.11.
Carver KA, Smith TL, Gallagher PE, Tallant EA.
Angiotensin-(1-7) reduces angiotensin II-induced remodeling of the microcirculation [abstract]. Hypertension.
2010;
56(5):e141-e142.
Nautiyal M, Katakam PV, Busija DW, Gallagher PE, Tallant EA, Chappell MC, Diz DI.
Oxidative stress and low expression of mitogen-activated protein kinase phosphatase-1 (MKP-1) in dorsal medulla of hypertensive (mRen2)27 transgenic rats [abstract]. Hypertension.
2010;
56(5):e156.
Cook KL, Soto PD, Gallagher P, Tallant EA.
Angiotensin-(1-7) inhibition of human breast tumors with distinct hormone receptor expression results in a differential regulation of AKT [abstract]. Cancer Res.
2009;
69(2 Suppl):240S.
Soto-Pantoja DR, Petty WJ, Gallagher PE, Tallant EA.
Angiotensin-(1-7) inhibits triple negative tumor growth through the inhibition of angiogenesis and a reduction in placental growth factor PIGF [abstract]. Cancer Res.
2009;
69(2 Suppl):103S.
Gallagher PE, Tallant EA.
Angiotensin-(1-7) reduces MAP kinase activity by upregulation of the dual-specificity phosphatase DUSP1 [abstract]. Hypertension.
2009;
54(4):e35.
Tallant EA, McCollum LT, Gallagher PE.
Angiotensin-(1-7) reduces Ang II-induced cardiac hypertrophy with an associated increase in the dual-specificity phosphatase 1 (DUSP1) [abstract]. Hypertension.
2009;
54(4):e122.
Petty WJ, Miller AA, McCoy TP, Gallagher PE, Tallant EA, Torti FM.
Phase I study of angiotensin-(1-7), an endogenous antiangiogenic hormone: clinical, pharmacokinetic, and biomarker findings [abstract]. Mol Cancer Ther.
2009;
8(12 Suppl 1):B208.
Lesser GJ, Carver KA, Newton SJ, Tallant EA, Gallagher PE.
Angiotensin-(1-7), a small molecule inhibitor of glioblastoma growth [abstract]. J Clin Oncol.
2009;
27(15 Suppl):2024.
Menon J, Miller MS, Soto-Pantoja DR, Callahan MF, Tallant EA, Gallagher PE.
Angiotensin-(1-7) reduces lung tumor incidence in a novel bitransgenic Ki-ras G12C mouse model of lung tumorigenesis through a reduction in cyclooxygenase-2 [abstract]. In: Proceedings of the 99th Annual Meeting of the American Association for Cancer Research; 2008 Apr 12-16; San Diego, CA. Philadelphia (PA): AACR.
2008;
():Abstr 4654.
Soto-Pantoja DR, Menon J, Gallagher PE, Tallant EA.
Angiotensin-(1-7) inhibits the growth of human triple negative breast tumors in an orthotopic model [abstract]. In: Proceedings of the 99th Annual Meeting of the American Association for Cancer Research ; 2008 Apr 12-16; San Diego (CA). Philadelphia (PA): AACR.
2008;
():Abstr 2416.
Petty WJ, Miller AA, McCoy TP, Gallagher PE, Tallant EA, Torti FM.
Bi-directional translational research with angiotensin-(1-7) uncovers placental growth factor as a therapeutic target [abstract]. In: Proceedings of the 99th Annual Meeting of the American Association for Cancer Research ; 2008 Apr 12-16; San Diego (CA). Philadelphia (PA): AACR.
2008;
():Abstr 4968.
Lesser G, Carver K, Newton S, Tallant EA, Gallagher P.
Angiotensin-(1-7) inhibits the growth of human glioblastoma xenografts in nude mice [abstract]. Neuro Oncol.
2008;
10(5):792.
Gallagher PE, Soto-Pantoja DR, Tallant EA.
Angiotensin-(1-7) reduces endothelial cell growth and migration and increases VEGI to inhibit angiogenesis [abstract]. Hypertension.
2008;
52(4):e72.
McCollum LT, Gallagher PE, Tallant EA.
Angiotensin-(1-7) attenuates cardiac fibrosis and vascular hypertrophy in a model of angiotensin II-dependent hypertension [abstract]. Hypertension.
2008;
52(4):e120.
Tallant EA, McCollum LT, Gallagher PE.
Angiotensin-(1-7) increases DUSP-1 and reduces the endothelin-1-mediated increase in COX-2 and PGES-1 in cardiac fibroblasts [abstract]. Hypertension.
2008;
52(4):e47-e48.
Trask AJ, Jessup JA, Tallant EA, Chappell MC, Ferrario CM.
Renin-independent processing of angiotensin-(1-12) in the rat heart and isolated myocytes [abstract]. Hypertension.
2008;
52(4):e45-e46.
Petty WJ, Miller AA, McCoy TP, Gallagher PE, Tallant EA, Torti FM.
Phase I trial of angiotensin-(1-7): an endogenous anti-angiogenic hormone [abstract]. J Clin Oncol.
2008;
26(15 Suppl):634s.
Gallagher PE, Soto-Pantoja DR, Tallant EA.
Angiotensin-(1-7) inhibits angiogenesis by reducing endothelial cell growth [abstract]. Hypertension.
2007;
50(4):e91.
Tallant EA, Gallagher PE.
Angiotensin-(1-7) upregulates the mitogen-activated phosphatase DUSP1 in vascular smooth muscle cells [abstract]. Hypertension.
2007;
50(4):e77.
Whaley-Connell AT, Chowdhury NA, Hayden MR, Stump CS, Habibi J, Wiedmeyer CE, Gallagher PE, Tallant EA, Cooper SA, Ferrario C, et al.
Oxidative stress and glomerular filtration barrier injury: role of the renin-angiotensin system in the Ren2 transgenic rat. Am J Physiol Renal Physiol.
2006;
291(6):F1308-1314.
Diz DI, Tommasi EN, Ferrario CM, Tallant EA, Gallagher PE.
ACE2 inhibition in the nucleus of the solitary tract reduces baroreceptor reflex sensitivity [abstract]. Hypertension.
2006;
48(4):e87.
Gallagher PE, Ferrario CM, Tallant EA.
Molecular mechanisms for the regulation of angiotensin converting enzyme 2 by angiotensin peptides in vascular smooth muscle cells [abstract]. Hypertension.
2006;
48(4):e72.
McCollum LT, Gallagher PE, Ferrario CM, Tallant EA.
Angiotensin-(1-7) reduces COX-2 in cardiac fibroblasts [abstract]. Hypertension.
2006;
48(4):e79.
Tallant EA, Menon J, Soto-Pantoja DR, Gallagher PE.
Angiotensin peptides and cancer. In: Kastin AJ, ed. Handbook of biologically active peptides.
Boston: Academic Press;
2006:
459-465.
Menon J, Tallant EA, Gallagher PE.
Experimental and molecular therapeutics 17: novel therapeutic targets [abstract]. In: Proceedings of the 97th Annual Meeting of the American Association for Cancer Research ; 2006 Apr 1-5; Washington, DC. Philadelphia (PA): AACR.
2006;
():Abstr 2160.
Soto-Pantoja DR, Gallagher PE, Tallant EA.
Inhibition of angiogenesis by angiotensin-(1-7) [abstract]. In: Proceedings of the 97th Annual Meeting of the American Association for Cancer Research ; 2006 Apr 1-5; Washington, DC. Philadelphia (PA): AACR.
2006;
():Abstr 950.
All Publications
For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.
For a list of earlier publications, visit the Carpenter Library Publication Search.